Literature DB >> 29329034

Long non-coding RNA CCAT2 promotes cholangiocarcinoma cells migration and invasion by induction of epithelial-to-mesenchymal transition.

Yi Xu1, Yue Yao2, Wei Qin1, Xiangyu Zhong3, Xingming Jiang4, Yunfu Cui5.   

Abstract

Cholangiocarcinoma (CCA) is one of the most aggressive malignancies in humans. Emerging evidence has indicated that abnormally expressed long non-coding RNAs (lncRNAs) could conduce to tumorigenesis and progression. Specifically, colon cancer-associated transcript 2 (CCAT2) has been reported to be overexpressed in several carcinomas. However, its clinical significance and functional roles in CCA is still unknown. qRT-PCR experiments were conducted to assess the CCAT2 expression in CCA tissue samples and cell lines. In addition, the link between CCAT2 expression and clinicopathological characteristics was analyzed. The potential effects of CCAT2 in CCA cells was evaluated in vitro including cell proliferation, colony-forming ability, apoptosis, migration, invasion and epithelial-to-mesenchymal transition (EMT). As a result, CCAT2 was aberrantly overexpressed in CCA tissue samples and cells, and this upregulation was correlated with tumor size, lymph node invasion, TNM stage and postoperative recurrence in CCA patients. Overexpression of CCAT2 could serve as an independent prognostic indicator for CCA. Additionally, overexpression of CCAT2 was a dismal prognostic indicator for patients with CCA. Furthermore, CCAT2 silencing caused tumor suppressive effects via reducing cell proliferation, migration and invasion, inducing cell apoptosis and reversing the EMT process in HuCCT1 and CCLP1 cells. Collectively, our data illustrated that lncRNA CCAT2 played an oncogenic role in CCA and may offer a potential therapeutic target for treating this fatal disease.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  CCAT2; Cholangiocarcinoma; EMT; Long non-coding RNA

Mesh:

Substances:

Year:  2018        PMID: 29329034     DOI: 10.1016/j.biopha.2018.01.061

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  10 in total

Review 1.  Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma.

Authors:  Yanhua Wu; Khizar Hayat; Yufei Hu; Jianfeng Yang
Journal:  Front Cell Dev Biol       Date:  2022-04-27

Review 2.  lncRNAs as potential molecular biomarkers in the clinicopathology and prognosis of cholangiocarcinoma: a systematic review and meta-analysis.

Authors:  Kangfu Dai; Jing Quan; Fangli Yan; Xinghan Jin; Xiang Pan; Xiaorui Song; Shijie Zhang; Qingqi Ren; Jikui Liu; Xiaoping Liu
Journal:  Onco Targets Ther       Date:  2019-03-08       Impact factor: 4.147

3.  A Comprehensive Exploration of the lncRNA CCAT2: A Pan-Cancer Analysis Based on 33 Cancer Types and 13285 Cases.

Authors:  Bowen Huang; Min Yu; Renguo Guan; Dong Liu; Baohua Hou
Journal:  Dis Markers       Date:  2020-02-24       Impact factor: 3.434

4.  The Interaction Between lncRNA SNHG1 and miR-140 in Regulating Growth and Tumorigenesis via the TLR4/NF-κB Pathway in Cholangiocarcinoma.

Authors:  Zhen Li; Xin Li; Xiao Du; Henghui Zhang; Zhengyang Wu; Kewei Ren; Xinwei Han
Journal:  Oncol Res       Date:  2019-02-14       Impact factor: 5.574

5.  Linc01513 inhibits the malignant potential of Nasopharyngeal carcinoma by binding to PTBP1.

Authors:  Juan Wang; Xiaolan Cai; Liqiang Zhang; Dapeng Lei
Journal:  J Cancer       Date:  2021-10-28       Impact factor: 4.207

6.  Construction of novel lncRNA-miRNA-mRNA ceRNA networks associated with prognosis of hepatitis C virus related hepatocellular carcinoma.

Authors:  Lishi Shao; Lei Liang; Qixiang Fang; Jiaping Wang
Journal:  Heliyon       Date:  2022-10-01

7.  LINC00491 as a new molecular marker can promote the proliferation, migration and invasion of colon adenocarcinoma cells.

Authors:  Jiahui Wan; Daiqian Deng; Xiuli Wang; Xiaojin Wang; Shijun Jiang; Rongjun Cui
Journal:  Onco Targets Ther       Date:  2019-08-13       Impact factor: 4.147

8.  lncRNA CCAT2 Enhanced Resistance of Glioma Cells Against Chemodrugs by Disturbing the Normal Function of miR-424.

Authors:  Jun Ding; Lin Zhang; Shiwen Chen; Heli Cao; Chen Xu; Xuyang Wang
Journal:  Onco Targets Ther       Date:  2020-02-17       Impact factor: 4.147

Review 9.  Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma.

Authors:  Yu-Chan Chang; Ming-Huang Chen; Chun-Nan Yeh; Michael Hsiao
Journal:  Biomolecules       Date:  2020-09-28

Review 10.  Emerging roles of long noncoding RNAs in cholangiocarcinoma: Advances and challenges.

Authors:  Yang Yang; Xueting Deng; Quanpeng Li; Fei Wang; Lin Miao; Qi Jiang
Journal:  Cancer Commun (Lond)       Date:  2020-11-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.